
Opinion|Videos|March 13, 2025
Personalizing ADC Therapy in mBC Based on Patient Characteristics and Prior Therapies
Panelists discuss how patient characteristics significantly impact antibody-drug conjugate (ADC) therapy selection, with key factors including the presence and location of brain metastases (due to blood-brain barrier penetration), organ function and comorbidities affecting toxicity risks, and prior treatment history that may influence both efficacy and safety. Treatment decisions require careful individualization.
Advertisement
Episodes in this series

Video content above has been prompted by the following:
- How do patient characteristics (eg, brain metastases, other comorbidities, prior therapies) influence ADC therapy selection?
Advertisement
Advertisement
Advertisement
Trending on Pharmacy Times
1
Yes, COVID-19 Is Still a Big Deal. Pharmacy Is the Tip of the Spear (and Needle)
2
Beat the Heat: 10 Common Medication Culprits Causing Heat Intolerance
3
FDA Fast Tracks First-in-Class TNFR2 Antibody as Chemotherapy-Free Strategy for Platinum-Resistant Ovarian Cancer
4
The Inflation Reduction Act and Oncology Drug Pricing: What Pharmacists Need to Know
5



































































































